RxDoctor Payments Data

Thomas Burkert, MD

Internal Medicine · Poland, OHNPI 1265493845

Payments from drug & device makers

$252in general payments, 2019–2025

Across 19 payments — averaging $13.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$53
  • Novo Nordisk$44
  • Boehringer Ingelheim$36
  • Amarin Pharma, Inc.$30
  • Lilly USA, LLC$26
  • Amgen$17
  • plus $47 from 4 others

What the payments were for

  • Food & beverage$252100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$252 in reported general payments places this provider in the 55th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$121,100
Medicare patients
280
Services billed
1,634

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban320$305,893
OzempicSemaglutide134$146,988
JanuviaSitagliptin Phosphate81$98,318
JardianceEmpagliflozin86$93,125
TrulicityDulaglutide41$40,504
XareltoRivaroxaban49$39,375
MounjaroTirzepatide31$37,233
SynthroidLevothyroxine Sodium176$10,915
Repatha SureclickEvolocumab12$9,847
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog24$9,368
Lantus SolostarInsulin Glargine,hum.Rec.Anlog48$8,344
Spiriva RespimatTiotropium Bromide13$7,051
Metoprolol Succinate382$6,716
Rosuvastatin Calcium448$6,151
Levothyroxine Sodium584$6,072

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$53$311,445342 claims
Novo NordiskOzempic$44$146,988134 claims
Boehringer IngelheimJardiance, Spiriva Respimat$36$100,17699 claims
MerckJanuvia$12$98,31881 claims
Lilly USA, LLCTrulicity, Mounjaro$26$77,73672 claims
Johnson & JohnsonXarelto$12$39,37549 claims
AstraZenecaSymbicort$11$4,68215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Poland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →